MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE Drug Patent Profile

Which patents cover Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate, and what generic alternatives are available?

Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is a drug marketed by Santarus and is included in one NDA.

The generic ingredient in MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is magnesium hydroxide; omeprazole; sodium bicarbonate. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium hydroxide; omeprazole; sodium bicarbonate profile page.

Summary for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE at DailyMed

Recent Clinical Trials for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Valeant Pharmaceuticals International, Inc.	Phase 4
Bausch Health Americas, Inc.	Phase 4
Yvonne Romero	Phase 4

See all MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE clinical trials

US Patents and Regulatory Information for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-001	Dec 4, 2009		DISCN	No	No
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-002	Dec 4, 2009		DISCN	No	No

Expired US Patents for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-001	Dec 4, 2009
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-001	Dec 4, 2009
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-002	Dec 4, 2009
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-002	Dec 4, 2009
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-002	Dec 4, 2009
Santarus	MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE	magnesium hydroxide; omeprazole; sodium bicarbonate	TABLET;ORAL	022456-001	Dec 4, 2009

International Patents for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

See the table below for patents covering MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	374832
Japan	4991432
European Patent Office	2201952
Cyprus	1107512
Norway	20023313
South Korea	20040099265

Supplementary Protection Certificates for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	C300615	Netherlands		PRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1020461	300482	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
0984957	1290006-4	Sweden		PRODUCT NAME: ACETYLSALICYLSYRA OCH ESOMEPRAZOLMAGNESIUMTRIHYDRAT; NAT. REG. NO/DATE: MTNR 44371 20110930; FIRST REG.: PT 5402359MFL 20110812
1499331	122014000007	Germany		PRODUCT NAME: NATRIUMSULFAT, MAGNESIUMSULFAT UND KALIUMSULFAT; NAT. REGISTRATION NO/DATE: 86203.00.00 20130808; FIRST REGISTRATION: BELGIEN BE434323 20130220

Market Dynamics and Financial Trajectory for Magnesium Hydroxide, Omeprazole, and Sodium Bicarbonate

Last updated: February 19, 2026

What Is the Current Market Size and Growth Outlook for Magnesium Hydroxide, Omeprazole, and Sodium Bicarbonate?

The global market for magnesium hydroxide, omeprazole, and sodium bicarbonate reflects various growth drivers and competitive landscapes within the pharmaceutical sector.

• Magnesium Hydroxide: Estimated global market size was approximately $480 million in 2022, driven by its use in antacids, laxatives, and PPE (personal protective equipment) manufacturing. Compound annual growth rate (CAGR) expected between 2023 and 2030 is around 3.8%.

• Omeprazole: The proton pump inhibitor (PPI) segment had a market size of approximately $8.6 billion in 2022. CAGR projected at 4.5%, propelled by chronic acid-related disorder treatments and OTC availability in key regions.

• Sodium Bicarbonate: The market stood at roughly $1.2 billion in 2022. It is used for acidity correction, emergency drug formulations, and industrial applications. Expected CAGR from 2023 to 2030 is 2.5%.

In total, these compounds’ combined market value exceeds $10 billion. Growth varies by geography, with Asia-Pacific showing the fastest expansion owing to rising healthcare access and manufacturing scaling.

How Are Market Drivers Shaping the Financial Trajectory?

Increased Prevalence of Acid Reflux and Gastrointestinal Disorders

The growth of acid reflux, GERD, and other gastrointestinal conditions sustains demand for magnesium hydroxide and omeprazole. Omeprazole accounts for roughly 60% of the PPI market share globally. Rising incidence in aging populations (notably in North America and Europe) sustains revenue streams.

OTC Accessibility and Patent Expirations

Many formulations of omeprazole, magnesium hydroxide, and sodium bicarbonate transitioned from prescription to OTC, broadening consumer access. Patent expiries for key brand names have enabled generic competition, leading to price erosion but increased volume sales.

Industrial Applications and Manufacturing

Magnesium hydroxide’s role beyond pharmaceuticals, especially in plastics, rubber, and fire-retardant materials, diversifies revenue sources. Sodium bicarbonate’s industrial use in pulp and paper, water treatment, and baking products maintains a steady demand, especially in emerging markets.

Patent Cliff and Market Entry

The expiry of patents for several formulations of omeprazole has led to the proliferation of generics. For example, bold patents in the U.S. expired in 2015, leading to increased competition and price reductions. The rise of biosimilars and alternative PPIs slightly tempers growth.

Regulatory Environment

Stringent regulations on manufacturing quality (e.g., FDA, EMA) influence operational costs and market entry speed. The trend toward stricter OTC and prescription drug policies affects sales channels.

R&D and New Formulations

Innovations like liquid, delayed-release, and combination products influence revenue. Firms investing in novel delivery mechanisms aim to differentiate products, encouraging further R&D investments worth hundreds of millions annually.

What Are the Major Market Players and Their Financial Strategies?

Leading Companies

• AbbVie: Dominates with omeprazole products, leveraging extensive patent portfolios and pipeline innovations.
• Pfizer: Historically a significant player, especially before patent expiries, with a diversified portfolio including OTC and prescription formulations.
• Reckitt Benckiser: Focuses on OTC magnesium hydroxide and sodium bicarbonate products.
• Dr. Reddy’s Laboratories: Acts as a key producer of generic omeprazole and magnesium hydroxide formulations, targeting emerging markets.

Mergers, Acquisitions, and Partnerships

In the past five years, deal activity includes:

• Acquisition: Reckitt’s acquisition of some OTC assets from Johnson & Johnson (2021), expanding market share in gastrointestinal products.
• Partnerships: Pfizer's collaboration with biotech firms to develop advanced PPI formulations (2022).

Revenue and Profit Trends

• The PPI segment (mainly omeprazole) generates approximately 80% of revenue for global PPI manufacturers.
• Magnesium hydroxide profit margins are influenced by raw material costs and regulatory compliance, averaging around 15-20%.
• Sodium bicarbonate margins are lower (~10%) due to commoditized pricing but benefit from industrial demands.

How Will Future Regulations and Innovations Influence Market Trajectory?

Innovations in drug delivery (delayed-release or combination products) are expected to command premium pricing and sustain revenue growth. However, upcoming patent expirations threaten to dilute revenues unless brands innovate.

Regulatory trends favoring OTC availability could expand accessible markets but require compliance investments, impacting short-term profitability.

Environmental regulations affecting manufacturing processes, especially for chemical producers, could entail additional costs. Areas like green chemistry and sustainable production are gaining importance.

Key Market Constraints and Risks

• Price pressures due to generic entry.
• Supply chain disruptions affecting raw materials.
• Regulatory hurdles for new formulations.
• Market saturation in mature regions leading to stagnant revenues.
• Competition from novel drug classes (e.g., H2 receptor antagonists, novel PPIs).

Summarized Forecasts

Compound	2022 Market Size	CAGR (2023-2030)	2030 Projection
Magnesium Hydroxide	$480 million	3.8%	~$650 million
Omeprazole	$8.6 billion	4.5%	~$12 billion
Sodium Bicarbonate	$1.2 billion	2.5%	~$1.5 billion

Key Takeaways

• The combined market exceeds $10 billion, with growth driven by aging populations, OTC expansion, and industrial applications.
• Patent expiries and generic proliferation constrain margins but stimulate volume growth.
• Innovation in formulations and healthcare regulatory policies shape future revenue streams.
• Companies with diversified portfolios across prescription, OTC, and industrial segments maintain resilience.
• Asia-Pacific emerges as a high-growth market due to expanding healthcare infrastructure and manufacturing.

FAQs

Q1: How does patent expiration impact the profitability of magnesium hydroxide and omeprazole?
A: Patent expirations enable generic competitors, lowering prices and margins but increasing volume. Companies must innovate or diversify to maintain profitability.

Q2: What are the primary drivers of growth in the sodium bicarbonate market?
A: Industrial uses in water treatment, baking, and pulp & paper sectors sustain demand, with some growth driven by emerging markets' infrastructure development.

Q3: Which regions hold the largest share of the market?
A: North America and Europe dominate in pharmaceuticals, while Asia-Pacific leads in manufacturing and rural healthcare expansion.

Q4: What technological innovations could influence future market dynamics?
A: Advanced drug delivery systems, combination products, and eco-friendly manufacturing processes can extend product lifecycles and margins.

Q5: How significant is the OTC market for these compounds?
A: OTC drugs for acid reflux and antacids constitute a substantial share, often exceeding 50% of total sales for omeprazole and magnesium hydroxide formulations.

---

References

[1] MarketsandMarkets. (2022). Gastrointestinal Therapeutics Market by Drug Class.
[2] Statista. (2023). Global Dental and Gastrointestinal Drug Market Sizes.
[3] Grand View Research. (2023). Antacid Market Analysis.
[4] U.S. Food & Drug Administration. (2022). Drug Approvals and Patent Data.
[5] Judd, F. (2021). Impact of Patent Expiry on the Proton Pump Inhibitor Market.